{"id":"NCT01254331","sponsor":"Hoffmann-La Roche","briefTitle":"An Open-label Study With Tocilizumab in Patients With Rheumatoid Arthritis in a Local Environment","officialTitle":"Open Label, Multicenter, Trial to Evaluate Safety, Tolerability and Efficacy of Tocilizumab in Monotherapy or in Combination With MTX in Patients With Active Rheumatoid Arthritis Who Have an Inadequate Response to Current Non Biologic DMARDs","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-02","primaryCompletion":"2013-02","completion":"2013-02","firstPosted":"2010-12-06","resultsPosted":"2015-02-26","lastUpdate":"2015-02-26"},"enrollment":51,"design":{"allocation":"NON_RANDOMIZED","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Rheumatoid Arthritis"],"interventions":[{"type":"DRUG","name":"tocilizumab [RoActemra]","otherNames":[]}],"arms":[{"label":"Single arm","type":"EXPERIMENTAL"}],"summary":"This open-label, multi-center study in a local environment will evaluate the safety and the effect on disease activity with regard to reduction in signs and symptoms over 6 months of treatment in patients with moderate to severe active rheumatoid arthritis who experienced an inadequate response to a non-biologic DMARD. Tocilizumab 8 mg/kg will be administered as an intravenous infusion every 4 weeks for a total of 6 infusions as monotherapy or in combination with methotrexate (MTX). The anticipated time of study treatment is 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Related AEs, Discontinuation Due to AEs, or Death","timeFrame":"Baseline, every 4 weeks through Week 52","effectByArm":[{"arm":"Tocilizumab","deltaMin":78.4,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":8},"locations":{"siteCount":6,"countries":["Tunisia"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":51},"commonTop":["Hypercholesterolemia","Hypertriglyceridemia","Increased ALT/AST","Skin and subcutaneous lesions","Neutropenia"]}}